Van Herk Rejects #ProQR Leadership
Van Herk Investments B.V., which holds over 10% of #ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
#proqr
Well.. if Van Herk is sufficiently pissed, he can call an EGM to remove both of them.
This month will be interesting.
#ProQR votes are out. deBoer (86.3%) + Shannon (80.7%) re-appointed as Directors. Should encourage corp governance discussion.
Only 78.5% of votes cast were in favor of authorizing Board to issue shares. Not sure the 'no' are aware that we are in the biotech business?
www.sec.gov/Archives/edg...
No, unfortunately. We should see the voting results soon. No filings yet. The message should be clear: more urgency, plus I want to see the NTCP preclinical package when #ProQR announce CTA.
#ProQR do you attend todays Annual General Meeting?
#proqr
Adage + Van Herk = 18.6%. Enough to outvote Lily.
What will they do to protect their crown jewel?
#ProQR
They changed delivery, so if the data gains by leaps and bounds, director term limits can take a backseat.
What I dont like is the Lily blackout even when there is progress payment of $1m in 1Q25.
#ProQR here is the van Herk letter. Makes important points, including violation of Dutch securities laws regarding Director term limits.
Annual Meeting next week.
www.sec.gov/Archives/edg...
I must say #ProQR is on probation right now. Having delayed clinical entry in this biotech environment was daring.
My demands:
1) It has to be for a substantially better candidate, show NHP data along with CTA news
2) CTA Q2 guidance must be met.
As an apparently long-time shareholder, he is disappointed with mgmt/Board performance, including not expanding Lilly deal and finding additional partnerships. #ProQR
Nice 80% #RNAediting efficiency in patient-derived cells at therapeutically relevant #oligonucleotide concentrations. If #ProQR can take advantage of #FDA platform pathway, #Rett opportunity very exciting.
#WaveLifeSciences, once saying they are out of correcting mutations, are also on it.
#ProQR had hoped to see NHP editing efficiencies for new AX-0810 #cholestatic disease candidate, but largely preclinical data with older (less potent candidate).
Guidance for CTA remains Q2 (though I am skeptical they can meet it) and topline data in Q4.
www.proqr.com/files/2025-0...
#ProQR said yesterday they are still in late stages of experiments ahead of CTA filing and data still on track for 2025.
So I expect CTA to slip into Q3. Today important presentation on what hope is the clinical candidate at #asgct25. #RNAediting
www.biotechtv.com/post/proqr-a...
I mentioned Prime and Beam because they can 'fix' genes with base and prime editing. Approach also applies to ADAR #RNAediting when targeted at individual mutations, e.g. in #RettSyndrome. #ProQR #WaveLifeSciences
Very satisfying to see progress on #RNAediting efficiencies. Also >50% in #RettSyndrome program. Just 2 years ago, 1-3% were top hits without ADAR overexpression.
#ProQR
#ProQR impressive preclinical AX-0810 cholestatic disease #ASGCT25 abstract. Clinical candidate shows >50% #RNAediting.
Robust changes in biomarkers (serum bile acids; conjugated/unconjugated ratio) already at less editing.
#prqr $prqr #proqr
Ok $155m raised. Thats around mkt cap of ADAR patent owner ProQR. How cheap.
airna.com/news/airna-r...
At what point will #Chinese biotechs buy up Western #biotechs with critical tech and IP, incl #PrimeMedicine and #ProQR?
$155M Series B investment into preclin #ADAR Therapeutics Co #Airna, highlighting strong interest in modality despite challenging biotech environment.
$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro
#ProQR another nice gain-of-function #RNAediting patent app, this time inspired by a human genetic variant in the #reelin gene conferring 'extreme resistance' to #Alzheimer's.
#ProQR unusual selling volume (2% of outstanding). 1.8 million shares traded so far today. Will it bottom today?
Q2 critical CTA/IND filing guidance with first human data expected in Q4 and cash runway into mid 2027...not worried here, it's in the company's hands.
#RNAediting patent app by #ProQR targeting gain-of-function in MC4R in the #CNS in #obesity.
patentscope.wipo.int/search/en/de...
